Association between Achilles Tendon Softness and Atherosclerotic Cardiovascular Disease in Patients with Familial Hypercholesterolemia

Journal of Atherosclerosis and Thrombosis ◽

10.5551/jat.63151 ◽

2022 ◽

Author(s):

Masahito Michikura ◽

Masatsune Ogura ◽

Mika Hori ◽

Kota Matsuki ◽

Hisashi Makino ◽

...

Keyword(s):

Cardiovascular Disease ◽

Achilles Tendon ◽

Familial Hypercholesterolemia ◽

Atherosclerotic Cardiovascular Disease

Download Full-text

Efficacy and Safety of Alirocumab in High-Risk Patients With Clinical Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia (from 5 Placebo-Controlled ODYSSEY Trials)

The American Journal of Cardiology ◽

10.1016/j.amjcard.2017.12.040 ◽

2018 ◽

Vol 121 (8) ◽

pp. 940-948 ◽

Author(s):

Peter A. McCullough ◽

Christie M. Ballantyne ◽

Santosh K. Sanganalmath ◽

Gisle Langslet ◽

Seth J. Baum ◽

...

Keyword(s):

Cardiovascular Disease ◽

High Risk ◽

Familial Hypercholesterolemia ◽

Atherosclerotic Cardiovascular Disease ◽

Efficacy And Safety ◽

High Risk Patients ◽

Heterozygous Familial Hypercholesterolemia ◽

Download Full-text

MODELLING THE U.S. POPULATION HEALTH BENEFITS OF FURTHER LOW-DENSITY LIPOPROTEIN CHOLESTEROL REDUCTION WITH ALIROCUMAB AMONG ATHEROSCLEROTIC CARDIOVASCULAR DISEASE OR HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA PATIENTS WITH ELEVATED LOW-DENSITY LIPOPROTEIN CHOLESTEROL

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(17)33455-1 ◽

2017 ◽

Vol 69 (11) ◽

pp. 66

Author(s):

Robert Sanchez ◽

Khurram Nasir ◽

Alexa Klimchak ◽

Andreas Kuznik ◽

Florence Joulain ◽

...

Keyword(s):

Cardiovascular Disease ◽

Familial Hypercholesterolemia ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Atherosclerotic Cardiovascular Disease ◽

Low Density ◽

Cholesterol Reduction ◽

Low Density Lipoprotein Cholesterol ◽

Download Full-text

TREATMENT EFFECTS OF ALIROCUMAB AS AN ADD-ON TO MAXIMALLY TOLERATED DOSE OF STATIN IN PATIENTS WITH HETEROZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA AND/OR ATHEROSCLEROTIC CARDIOVASCULAR DISEASE

Journal of the American College of Cardiology ◽

10.1016/s0735-1097(17)33543-x ◽

2017 ◽

Vol 69 (11) ◽

pp. 154

Author(s):

Robert J. Weiss ◽

Seth Baum ◽

Dirk Blom ◽

Jean Bergeron ◽

Gisle Langslet ◽

...

Keyword(s):

Cardiovascular Disease ◽

Familial Hypercholesterolemia ◽

Treatment Effects ◽

Atherosclerotic Cardiovascular Disease ◽

Heterozygous Familial Hypercholesterolemia

Download Full-text

Longitudinal treatment patterns among US patients with atherosclerotic cardiovascular disease or familial hypercholesterolemia initiating lipid-lowering pharmacotherapy

Journal of Clinical Lipidology ◽

10.1016/j.jacl.2016.09.002 ◽

2016 ◽

Vol 10 (6) ◽

pp. 1470-1480.e3 ◽

Author(s):

James P. Burke ◽

Ross J. Simpson ◽

Carly J. Paoli ◽

Jeffrey T. McPheeters ◽

Shravanthi R. Gandra

Keyword(s):

Cardiovascular Disease ◽

Familial Hypercholesterolemia ◽

Treatment Patterns ◽

Lipid Lowering ◽

Atherosclerotic Cardiovascular Disease ◽

Longitudinal Treatment

Download Full-text

low Density Lipoprotein Cholesterol Levels Among Patients with Clinical Atherosclerotic Cardiovascular Disease and Heterozygous Familial Hypercholesterolemia Post Statin Therapy

Value in Health ◽

10.1016/j.jval.2016.03.155 ◽

2016 ◽

Vol 19 (3) ◽

pp. A58

Author(s):

BH Johnson ◽

MM Bonafede ◽

N Princic ◽

DJ Harrison ◽

B Boatman ◽

...

Keyword(s):

Cardiovascular Disease ◽

Statin Therapy ◽

Familial Hypercholesterolemia ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Lipoprotein Cholesterol ◽

Atherosclerotic Cardiovascular Disease ◽

Low Density ◽

Low Density Lipoprotein Cholesterol ◽

Cholesterol Levels

Download Full-text

Effects of Switching to a Second High Intensity Statin on Low Density Lipoprotein Cholesterol Levels in Clinical Practice in Patients with Clinical Atherosclerotic Cardiovascular Disease or Heterozygous Familial Hypercholesterolemia

Journal of Clinical Lipidology ◽

10.1016/j.jacl.2017.04.081 ◽

2017 ◽

Vol 11 (3) ◽

pp. 821

Author(s):

Navneet Upadhyay ◽

Jeetvan Patel ◽

David Harrison

Keyword(s):

Cardiovascular Disease ◽

Clinical Practice ◽

Familial Hypercholesterolemia ◽

High Intensity ◽

Low Density Lipoprotein ◽

Density Lipoprotein ◽

Atherosclerotic Cardiovascular Disease ◽

Low Density ◽

Low Density Lipoprotein Cholesterol ◽

Cholesterol Levels

Download Full-text

CRT-800.02 Eligibility for PCSK9 Treatment in 734 Hypercholesterolemic Patients Referred to a Regional Cholesterol Treatment Center With Heterozygous Familial Hypercholesterolemia With LDL Cholesterol >100 Mg/dl and/or Atherosclerotic Cardiovascular Disease With LDL Cholesterol >70 Mg/dl Despite Maximal Tolerated Cholesterol Lowering Therapy

JACC Cardiovascular Interventions ◽

10.1016/j.jcin.2015.12.197 ◽

2016 ◽

Vol 9 (4) ◽

pp. S61-S62

Author(s):

Marloe Prince ◽

Charles Glueck ◽

Parth Shah ◽

Kevin Lee ◽

Vybhav Jetty ◽

...

Keyword(s):

Cardiovascular Disease ◽

Familial Hypercholesterolemia ◽

Ldl Cholesterol ◽

Treatment Center ◽

Atherosclerotic Cardiovascular Disease ◽

Cholesterol Lowering ◽

Heterozygous Familial Hypercholesterolemia ◽

Lowering Therapy ◽

Cholesterol Treatment

Download Full-text

Prediction of Familial Hypercholesterolemia in Patients at High Atherosclerotic Cardiovascular Disease Risk Using a Recently Validated Algorithm

CJC Open ◽

10.1016/j.cjco.2019.05.006 ◽

2019 ◽

Vol 1 (4) ◽

pp. 190-197

Author(s):

Latifah Alothman ◽

Magdaline Zawadka ◽

Sumayah Aljenedil ◽

Mahesh Kajil ◽

David Bewick ◽

...

Keyword(s):

Cardiovascular Disease ◽

Familial Hypercholesterolemia ◽

Disease Risk ◽

Cardiovascular Disease Risk ◽

Atherosclerotic Cardiovascular Disease ◽

Atherosclerotic Cardiovascular Disease Risk

Download Full-text

Management in der Gefäßmedizin – Therapie mit PCSK9-Inhibitoren derzeit unwirtschaftlich für US-Gesundheitssystem

Gesundheitsökonomie & Qualitätsmanagement ◽

10.1055/s-0043-112241 ◽

2017 ◽

Vol 22 (03) ◽

pp. 126-126

Author(s):

Gabriele Dobler

Keyword(s):

Cardiovascular Disease ◽

Cost Effectiveness ◽

Familial Hypercholesterolemia ◽

Inhibitor Therapy ◽

Atherosclerotic Cardiovascular Disease ◽

Pcsk9 Inhibitor ◽

Heterozygous Familial Hypercholesterolemia

Kazi DS et al. Cost-effectiveness of PCSK9 Inhibitor Therapy in Patients With Heterozygous Familial Hypercholesterolemia or Atherosclerotic Cardiovascular Disease. JAMA 2016; 316: 743–753 PCSK9-Inhibitoren wurden kürzlich in den USA für Patienten mit familiärer Hypercholesterinämie (FH) oder atherosklerotischer kardiovaskulärer Erkrankung (ASCVD) zugelassen, die trotz Maximaldosen von Statinen eine weitere Senkung des LDL-Cholesterins benötigen. Langfristig könnten sie wichtig bei der ASCVD-Prophylaxe werden. Die Autoren untersuchten die langfristige Wirtschaftlichkeit und potentiellen Kosten für das US-Gesundheitssystem.

Download Full-text

Atherosclerotic cardiovascular disease risk assessment in familial hypercholesterolemia

Current Opinion in Lipidology ◽

10.1097/mol.0000000000000553 ◽

2018 ◽

Vol 29 (6) ◽

pp. 445-452 ◽

Author(s):

Pedro Mata ◽

Rodrigo Alonso ◽

Leopoldo Pérez de Isla

Keyword(s):

Cardiovascular Disease ◽

Risk Assessment ◽

Familial Hypercholesterolemia ◽

Disease Risk ◽

Cardiovascular Disease Risk ◽

Atherosclerotic Cardiovascular Disease ◽

Atherosclerotic Cardiovascular Disease Risk

Download Full-text